Prof. Bernard Gersh analyses the current situation of clinical trials and beneficts within the XVIII International Symposium on Ischemic Heart Disease.
- Nowadays there is an overwhelming number of clinical trials available to physicians, however its impact on clinical practice seems quite limited. What are your thoughts on this?
- We have seen many very promising drugs, with a solid investigational backgroud, failing to demonstrate a clinical benefit in randomized clinical trials. What is the reason? Are we asking these drugs too much?